rejuvant life tabs

Simulations open the door to cell aging reversal

Latest articles

Paving the way to future organ factories

Extracellular matrix obtained by controlled decellularisation is used to reconstruct the liver with human-like characteristics, paving the way for transplantable livers. Researchers at the Human...

Charles Brenner: the journey from NR to Tru Niagen

Dr Charles Brenner, the developer of the intellectual property behind ChromaDex's Tru Niagen, on all things metabolism, NAD and NR clinical trials. Longevity.Technology: Following the...

Longevity investment firm announces acceleration programme

Call for future founders: longevity investment fund LongeVC announces in-house acceleration programme. LongeVC – a longevity investment group backed by an advisory board with solid...

The placenta: a limitless source of stem cells?

Part 1 of our exclusive interview with Celularity founder Dr Robert Hariri covers the discovery of placental pluripotent stem cells and the journey towards...

Most read

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...
Supplement report

Editor's picks

Paving the way to future organ factories

Extracellular matrix obtained by controlled decellularisation is used to reconstruct the liver with human-like characteristics, paving the way for transplantable livers. Researchers at the Human...

Charles Brenner: the journey from NR to Tru Niagen

Dr Charles Brenner, the developer of the intellectual property behind ChromaDex's Tru Niagen, on all things metabolism, NAD and NR clinical trials. Longevity.Technology: Following the...

Longevity investment firm announces acceleration programme

Call for future founders: longevity investment fund LongeVC announces in-house acceleration programme. LongeVC – a longevity investment group backed by an advisory board with solid...
Rejuvant

Switching off a newly-identified enzyme could reverse senescence, spotlighting a potential therapy avenue.

Researchers at the Korea Advanced Institute of Science and Technology (KAIST) have modelled molecular interactions in a simulation, identifying an enzyme that could be targeted to reverse senescence.

Longevity.Technology: The possibility of slowing and reversing senescence has led to huge interest in researching senolytic drugs. By blocking an enzyme and inhibiting a pathway, the team were able to ‘awaken’ senescent cells, triggering a re-establishing of a normal cell cycle, without tipping over into cancer. Although a long way from therapy, understanding this pathway could help develop future senolytics, and by researching fibroblasts, could mean possible future non-invasive topical applications.

Senescence is aging on a biological level with a dangerous twist; senescent cells are cells that that grown old and stopped dividing, but that failed to get the body’s death memo. Although this lack of proliferation helps to stop tumours forming, senescent cells emit dangerous toxins and chemicals and encourage other cells to also move into a senescent state. Senescent cells can be caused by DNA damage, telomere erosion, inflammatory cytokines, or oxidative or genotoxic stress, or oncogenic activation.

Several Longevity research approaches are focused on finding the sweet spot between reversing cellular senescence and trigging malignance that could become cancer.

 


 

“Our research opens the door for a new generation that perceives aging as a reversible biological phenomenon,”

 


 

Professor Cho and his colleagues at KAIST wanted a library of molecular targets that would be the best candidates for cellular senescence reversal. They collated results from their research into the molecular processes and pathways concerned with the cell division, quiescence (cells in a rest period, which aren’t currently dividing, but can be reactivated and enter the cell cycle again) and senescence of skin fibroblasts. Skin fibroblasts are particularly efficient at repairing wounds and skin damage.

Their own results were augmented with senescence information from a range of papers and databases and using algorithms, the KAIST scientists developed a model which is able simulate the interactions between these molecules, predicting which molecules could be targeted to wind back cell senescence.

Elevant

Focusing on one of the molecules, an enzyme called PDK1, the research team investigated it through incubated senescent skin fibroblasts and three-dimensional skin equivalent tissue models.

Using phospho-protein array experiments, Cho and his team discovered that blocking PDK1 caused the inhibition of two downstream signalling molecules; this in turn resulted in a restoration of the cells’ ability to go back into the cell cycle. In addition, the cells retained their capacity to regenerate injured skin, but didn’t proliferate in a malignant fashion [1].

According to the paper, which was published recently by Proceedings of the National Academy of Sciences (PNAS), the results “showed that PDK1 inhibition eradicates senescence hallmarks by suppressing both nuclear factor κB and mTOR signaling through the inactivation of a positive feedback loop composed of PDK1, AKT, IKBKB, and PTEN, resulting in restored skin regeneration capacity [1].”

The next step will be to investigate the full effect of PDK1 inhibition in organs and organisms. The gene that codes for PDK1 production is overexpressed in some cancers, so the KAIST team hope that inhibiting it will demonstrate anti-cancer effects, as well as anti-aging ones. have both anti-aging and anti-cancer effects.

Elevant

“Our research opens the door for a new generation that perceives aging as a reversible biological phenomenon,” says lead researcher Professor Kwang-Hyun Cho of the Department of Bio and Brain Engineering at KAIST.

[1] https://www.pnas.org/content/117/49/31535

Image credit: totojang1977 / Shutterstock
Eleanor Garth
Deputy Editor Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.
Rejuvant

Most popular

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...

Is nicotinamide riboside a safe and effective way to combat aging?

ChromaDex executive highlights the importance of clinical studies to prove the benefits of NAD+ boosting compound. ChromaDex is the company behind the popular healthy aging...
Supplement report

Related articles

Paving the way to future organ factories

Extracellular matrix obtained by controlled decellularisation is used to reconstruct the liver with human-like characteristics, paving the way for transplantable livers. Researchers at the Human...

The placenta: a limitless source of stem cells?

Part 1 of our exclusive interview with Celularity founder Dr Robert Hariri covers the discovery of placental pluripotent stem cells and the journey towards...

Insulin – predictor of longevity

Body weight stands for far more than simple aesthetics – it is key for longevity. From a single cell to a fully functioning human adult,...

Juvenescence debuts ketosis longevity supplement drink

Biotech Juvenescence's new product Metabolic Switch is a drink that supports healthy aging and a healthy metabolism by generating a state of ketosis. It's been...

Targeting neurodegeneration with $82m Series A

Alchemab raises £60 million to advance novel platform for identifying disease-modifying antibody therapeutics for neurodegeneration, cancer and more. UK-based biotech Alchemab Therapeutics has secured a...
Supps report ad middle